Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Subscribe To Our Newsletter & Stay Updated
